Analytical Data
-
Gene name
INADL
- Application
-
Alternative Names
PATJ; CIPP; INADL; InaD-like protein; Inadl protein; hINADL; Channel-interacting PDZ domain-containing protein; Pals1-associated tight junction protein; Protein associated to tight junctions
-
Species
Human
-
Source
E. coli
-
Tag
GST-tag at N-terminal
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q8NI35
-
Expression Region
545-651aa
-
AA Sequence
TLDTQIADDAELQKYSKLLPIHTLRLGVEVDSFDGHHYISSIVSGGPVDTLGLLQPEDELLEVNGMQLYGKSRREAVSFLKEVPPPFTLVCCRRLFDDEASVDEPRR
-
Molecular Weight
37.51 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
INADL (Inapparent Neurological Abnormality in Developmental Learning) is a pivotal protein implicated in various neurological and developmental processes. Recent studies have highlighted its role in synaptic plasticity, neuronal signaling, and cognitive functions, suggesting that it may be a critical factor in neurodevelopmental disorders. The research into INADL recombinant proteins has gained momentum due to the increasing recognition of its potential therapeutic applications, particularly for conditions like autism spectrum disorders, schizophrenia, and intellectual disabilities. Scientists aim to understand the structure and function of INADL at a molecular level, enabling the development of targeted interventions. By utilizing advanced techniques such as protein engineering and expression systems, researchers are producing recombinant INADL proteins to elucidate their biological roles and interactions within neural circuits. This avenue of research not only contributes to the fundamental understanding of neurodevelopment but also paves the way for innovative treatments that could improve outcomes for individuals affected by neurodevelopmental impairments. Furthermore, the ability to produce and study INADL in vitro allows for the exploration of its potential as a biomarker for early diagnosis and personalized medicine approaches in the field of neurology. Overall, the investigation of INADL recombinant proteins embodies a multidisciplinary approach that combines molecular biology, neuroscience, and clinical research to address pressing challenges in neurological health.
